Literature DB >> 11093746

Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.

T Berg1, A Mas Marques, M Höhne, B Wiedenmann, U Hopf, E Schreier.   

Abstract

Both a double-stranded RNA-dependent protein kinase (PKR)-phosphorylation homology domain (PePHD) within the E2 protein and a PKR-binding domain within the nonstructural 5A (NS5A) protein of hepatitis C virus (HCV) genotype 1 isolates inhibit the function of the interferon alfa (IFN-alpha)-induced antiviral effector protein PKR in vitro. We investigated whether the mutational pattern of the E2 region (codons 618-681, including PePHD) of 81 HCV genotype 1-infected patients (HCV-1b [n = 54], HCV-1a [n = 27]) influences the response to IFN-alpha. Initial viral decline (DeltaHCV RNA) was determined at week 1 hereby covering the effector reactions of IFN-alpha-mediated first phase and the immune-mediated second phase. DeltaHCV RNA less than 50% (group 1); DeltaHCV RNA greater than 50% but less than 90% (group 2); and DeltaHCV RNA > or =90% (group 3) were differentiated. The PePHD region was highly conserved; the few mutations (5 patients) did not correlate with DeltaHCV RNA or sustained virologic response to IFN-alpha. Within the flanking regions before and after PePHD (codons 618-681) 72 of 81 patients (89%) had 2.6+/-0.17 mutations (median, 3; range, 1-8) that did not correlate with treatment response. Sequence analysis of the NS5A protein (codons 2,209-2,274, including interferon sensitivity determining region [ISDR]) in 39 of 81 patients showed a higher mean number of mutations in the ISDR (codons 2,209-2,248) in groups 2 (1.28+/- 0.43 [n = 18]) and 3 (1.89+/-0.54 [n = 9]) than in group 1 (0.67+/- 0.19 [n = 12]; P =.049 group 1 vs. 3) and a mutant type ISDR (e.g., > or =4 mutations) was significantly more frequent in sustained virologic responders than in nonresponders or relapsers (2 of 4 [50%] vs. 2 of 35 [6%]; P =.045). Thus, NS5A appears to be functionally relevant in IFN-alpha-induced effector reactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093746     DOI: 10.1053/jhep.2000.20527

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

Review 1.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection.

Authors:  Anzar Ashraf; Anita Chakravarti; Priyamvada Roy; Premashish Kar; Oves Siddiqui
Journal:  Virusdisease       Date:  2016-08-06

3.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

4.  Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.

Authors:  Koji Ukai; Masatoshi Ishigami; Kentaro Yoshioka; Naoto Kawabe; Yoshiaki Katano; Kazuhiko Hayashi; Takashi Honda; Motoyoshi Yano; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.

Authors:  Catherine Gaudy; Marie Lambelé; Alain Moreau; Pascal Veillon; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

6.  The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy.

Authors:  Phillip S Pang; Paul J Planet; Jeffrey S Glenn
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

7.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.

Authors:  M Pascu; P Martus; M Höhne; B Wiedenmann; U Hopf; E Schreier; T Berg
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

8.  Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.

Authors:  Maureen J Donlin; Nathan A Cannon; Ermei Yao; Jia Li; Abdus Wahed; Milton W Taylor; Steven H Belle; Adrian M Di Bisceglie; Rajeev Aurora; John E Tavis
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

9.  Regulation of PKR and IRF-1 during hepatitis C virus RNA replication.

Authors:  Jill Pflugheber; Brenda Fredericksen; Rhea Sumpter; Chunfu Wang; Felecia Ware; Donald L Sodora; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

10.  Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response.

Authors:  Cíntia Bittar; Ana Carolina G Jardim; Lilian H T Yamasaki; Artur T L de Queiróz; Claudia M A Carareto; João Renato R Pinho; Isabel Maria V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2010-02-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.